Evidence map›Paper›PMID 36475576›Full record

ArticleACS applied materials & interfaces2022

Aptamer-Functionalized Ce

Yu Ouyang, Michael Fadeev, Pu Zhang, Raanan Carmieli, Yang Sung Sohn, Ola Karmi, Yunlong Qin, Xinghua Chen, Rachel Nechushtai, Itamar Willner

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Nucleic Acid-Modified Nanoparticles for Cancer Therapeutic Applications.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yu OuyangThe Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.ORCID 0000-0002-2418-281X
Michael FadeevThe Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Pu ZhangThe Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Raanan CarmieliDepartment of Chemical Research Support, Weizmann Institute of Science, Rehovot 76100, Israel.ORCID 0000-0003-4418-916X
Yang Sung SohnInstitute of Life Science, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Ola KarmiInstitute of Life Science, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Yunlong QinThe Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Xinghua ChenThe Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Rachel NechushtaiInstitute of Life Science, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.ORCID 0000-0002-3219-954X
Itamar WillnerThe Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.ORCID 0000-0001-9710-9077

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aptamer-functionalized Ce

Indexed as

Antineoplastic AgentsAptamers, NucleotideBreast NeoplasmsDopamineFemaleHumansHydrogen PeroxidePeroxidasePeroxidasesAntineoplastic AgentsAptamers, NucleotideDopamineHydrogen PeroxidePeroxidasePeroxidasesaptamerchemodynamic cancer therapynanozymeperoxidasereactive oxygen species

Identifiers

PMID36475576
PMCPMC9782376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.